Program
Optimized Background Regimen (OBR)
Its studies are led by Gilead Sciences.
Furthest: phase 3, since Oct 28, 20192 company-led studies, 2 open or runningNext primary completion: Mar 2027 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciences | 22 open or running | phase 3since Oct 28, 2019 | Oct 28, 2019 | Mar 2027phase 2 · NCT06749054 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 28, 2019First study: phase 3 study in HIV-1-infectionFirst studyNCT04150068 · 72 enrolled · United States, Canada, Dominican Republic and more
- Dec 19, 2024Phase 2 study in HIV-1-infectionNCT06749054 · 12 planned · United States, South Africa
Ahead
- Mar 2027Primary completion: phase 2 study in HIV-1-infectionNCT06749054
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06749054HIV-1-infection · United States, South Africa | 2 | Recruiting | Mar 2027 | 12 |
| NCT04150068HIV-1-infection · United States, Canada, Dominican Republic and more | 3 | Active, not recruiting | Oct 5, 2020 | 72 |
How it is read
Names in the registry
- “Optimized Background Regimen (OBR)”, 2 entries
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.